Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 27, 2021 08:30 ET | Source: CMI

Global Interstitial Lung Disease Market to Surpass US$ 2453.5 Million by 2028, Says Coherent Market Insights (CMI)

SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected...
August 14, 2018 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update

SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
August 08, 2018 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018

SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
July 31, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer

SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
June 26, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr...
May 17, 2018 07:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference

SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
November 27, 2017 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
November 14, 2017 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
October 01, 2015 09:05 ET | Source: UCHealth

University of Colorado Hospital Announces new Center for Lungs and Breathing

AURORA, COLO., Oct. 1, 2015 (GLOBE NEWSWIRE) -- UCHealth's University of Colorado Hospital (UCH), a national leader in pulmonology, cancer and upper airway disorders, opens its new multidisciplinary...